UBS analyst David Dai raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $7.00 (from $4.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE